RT Journal Article
SR Electronic
T1 Impact of opioid overdoses on US life expectancy and years of life lost, by demographic group and stimulant co-involvement: a mortality data analysis from 2019-2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.07.23292297
DO 10.1101/2023.07.07.23292297
A1 Hébert, Anne H.
A1 Hill, Alison L.
YR 2024
UL http://medrxiv.org/content/early/2024/05/26/2023.07.07.23292297.abstract
AB Background The United States’ opioid crisis is worsening, and the number of deaths reached 81,806 in 2022 after more than tripling over the past decade. This study aimed to comprehensively characterize changes in burden of opioid overdose mortality in terms of life expectancy reduction and years of life lost between 2019-2022, including differential burden across demographic groups and the contribution of polysubstance use.Methods Using life tables and counts for all-cause and opioid overdose deaths from the National Center for Health Statistics, we constructed cause-eliminated life tables to estimate mortality by age in the absence of opioid-related deaths. We calculated the loss in life expectancy at birth (LLE) and total years of life lost (YLL) due to opioid overdose deaths by state of residency, sex, racial/ethnic group, and co-involvement of cocaine and psychostimulants.Findings Opioid-related deaths in the US led to an estimated 3·1 million years of life lost in 2022 (38 years per death), compared to 2·0 million years lost in 2019. Relative to a scenario with no opioid mortality, we estimate that opioid-related deaths reduced life expectancy nationally by 0·67 years in 2022 vs 0·52 years in 2019. This LLE worsened in all racial/ethnic groups during the study period: 0·76y to 0·96y for white men, 0·36y to 0·55y for white women, 0·59y to 1·1y for Black men, 0·27y to 0·53y for Black women, 0·31y to 0·82y for Hispanic men, 0·19y to 0·31y for Hispanic women, 0·62y to 1·5y for American Indian/Alaska Native (AI/AN) men, 0·43y to 1y for AI/AN women, 0·09y to 0·2y for Asian men, and 0.08y to 0.13y for Asian women. Nearly all states experienced an increase in years of life lost (YLL) per capita from 2019-2022, with YLL more than doubling in 16 states. Cocaine or psychostimulants with abuse potential (incl. methamphetamines) were involved in half of all deaths and years of life lost in 2022, with substantial variation in the predominant drug class by state and racial/ethnic group.Interpretation The burden of opioid-related mortality increased dramatically in the US between 2019-2022, coinciding with the period of the COVID-19 pandemic and the associated disruptions to social, economic, and health systems. Opioid overdose deaths are an important contributor to decreasing US life expectancy, and Black, Hispanic, and Native Americans now experience mortality burdens approaching or exceeding white Americans.Funding NoneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: https://wonder.cdc.gov/mcd.html and https://www.cdc.gov/nchs/nvss/life-expectancy.htmI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesOur code is open access on GitHub: https://github.com/annehebert/OpioidsYLL All data produced in the present study are available upon reasonable request to the authors, and are available online at: https://wonder.cdc.gov/mcd-icd10-expanded.html https://www.cdc.gov/nchs/nvss/life-expectancy.htm https://github.com/annehebert/OpioidsYLL https://wonder.cdc.gov/mcd-icd10-expanded.html https://www.cdc.gov/nchs/nvss/life-expectancy.htm